 Objective: Age-related macular degeneration AMD, the leading cause of blindness in people over age 65 in the United States, is a heterogeneous clinical entity in which retinal degeneration occurs predominantly in the macula in the context of aging and leads to impairment of central visual acuity VA. AMD occurs in two general forms, one of which involves choroidal neovascularization CNV with subsequent formation of a disciform scar. This is often referred to as the neovascular or wet form. A second form, the subject of this study, is termed dry atrophic macular degeneration or otherwise geographic atrophy GA and involves a slow progressive atrophy of retinal pigment epithelial RPE cells and photoreceptors in the macula, also resulting in central vision loss. GA is estimated to affect up to 1 million persons in the U.S. and there is no current treatment that can prevent its onset or retard its progression. While the etiology of GA is not completely understood, inflammatory processes involving the activation of resident immune cells of the retina called microglia is likely to contribute. Minocycline inhibits the activation of microglia which produce inflammatory factors implicated in GA development. The objective of this study is to investigate the safety and possible efficacy of oral minocycline in patients with GA. 